152 related articles for article (PubMed ID: 31924700)
1. Characteristics and Outcome of
Smyth LM; Zhou Q; Nguyen B; Yu C; Lepisto EM; Arnedos M; Hasset MJ; Lenoue-Newton ML; Blauvelt N; Dogan S; Micheel CM; Wathoo C; Horlings H; Hudecek J; Gross BE; Kundra R; Sweeney SM; Gao J; Schultz N; Zarski A; Gardos SM; Lee J; Sheffler-Collins S; Park BH; Sawyers CL; André F; Levy M; Meric-Bernstam F; Bedard PL; Iasonos A; Schrag D; Hyman DM;
Cancer Discov; 2020 Apr; 10(4):526-535. PubMed ID: 31924700
[TBL] [Abstract][Full Text] [Related]
2. Letting the GENIE Out of Its Bottle: Examining the Potential of Real-World Clinicogenomic Data.
Castellanos E; Baxi SS
Cancer Discov; 2020 Apr; 10(4):490-491. PubMed ID: 32238395
[TBL] [Abstract][Full Text] [Related]
3. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
Smyth LM; Tamura K; Oliveira M; Ciruelos EM; Mayer IA; Sablin MP; Biganzoli L; Ambrose HJ; Ashton J; Barnicle A; Cashell DD; Corcoran C; de Bruin EC; Foxley A; Hauser J; Lindemann JPO; Maudsley R; McEwen R; Moschetta M; Pass M; Rowlands V; Schiavon G; Banerji U; Scaltriti M; Taylor BS; Chandarlapaty S; Baselga J; Hyman DM
Clin Cancer Res; 2020 Aug; 26(15):3947-3957. PubMed ID: 32312891
[TBL] [Abstract][Full Text] [Related]
4. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
Rudolph M; Anzeneder T; Schulz A; Beckmann G; Byrne AT; Jeffers M; Pena C; Politz O; Köchert K; Vonk R; Reischl J
BMC Cancer; 2016 Aug; 16():622. PubMed ID: 27515171
[TBL] [Abstract][Full Text] [Related]
5. AKT Inhibition in Solid Tumors With AKT1 Mutations.
Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
[TBL] [Abstract][Full Text] [Related]
6. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer.
Thirumal Kumar D; Jain N; Evangeline J; Kamaraj B; Siva R; Zayed H; George Priya Doss C
Comput Biol Med; 2019 Dec; 115():103513. PubMed ID: 31698236
[TBL] [Abstract][Full Text] [Related]
7. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.
Kim MS; Jeong EG; Yoo NJ; Lee SH
Br J Cancer; 2008 May; 98(9):1533-5. PubMed ID: 18392055
[TBL] [Abstract][Full Text] [Related]
9. AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling.
Gao SP; Kiliti AJ; Zhang K; Vasani N; Mao N; Jordan E; Wise HC; Shrestha Bhattarai T; Hu W; Dorso M; Rodrigues JA; Kim K; Hanrahan AJ; Razavi P; Carver B; Chandarlapaty S; Reis-Filho JS; Taylor BS; Solit DB
Mol Cancer Res; 2021 Apr; 19(4):573-584. PubMed ID: 33303690
[TBL] [Abstract][Full Text] [Related]
10. Effects of AKT1 E17K mutation hotspots on the biological behavior of breast cancer cells.
Wu W; Chen Y; Huang L; Li W; Tao C; Shen H
Int J Clin Exp Pathol; 2020; 13(3):332-346. PubMed ID: 32269671
[TBL] [Abstract][Full Text] [Related]
11. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.
Malanga D; Scrima M; De Marco C; Fabiani F; De Rosa N; De Gisi S; Malara N; Savino R; Rocco G; Chiappetta G; Franco R; Tirino V; Pirozzi G; Viglietto G
Cell Cycle; 2008 Mar; 7(5):665-9. PubMed ID: 18256540
[TBL] [Abstract][Full Text] [Related]
12. Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.
Shimoi T; Hashimoto J; Sudo K; Shimomura A; Noguchi E; Shimizu C; Yunokawa M; Yonemori K; Yoshida H; Yoshida M; Kato T; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
BMC Cancer; 2021 Oct; 21(1):1131. PubMed ID: 34670536
[TBL] [Abstract][Full Text] [Related]
13. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
14. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
[TBL] [Abstract][Full Text] [Related]
15. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
16. Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer.
Bose S; Kalinsky K
Clin Breast Cancer; 2021 Jun; 21(3):e150-e153. PubMed ID: 33177006
[No Abstract] [Full Text] [Related]
17. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
[TBL] [Abstract][Full Text] [Related]
18. A gain of function mutation in AKT1 increases hexokinase 2 and diminishes oxidative stress in meningioma.
Singh S; Lathoria K; Umdor SB; Singh J; Suri V; Sen E
Cytokine; 2024 Apr; 176():156535. PubMed ID: 38325141
[TBL] [Abstract][Full Text] [Related]
19. AKT1(E17K) in human solid tumours.
Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
[TBL] [Abstract][Full Text] [Related]
20. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
